Cargando…

Systemic Biomarkers of Neutrophilic Inflammation, Tissue Injury and Repair in COPD Patients with Differing Levels of Disease Severity

The identification and validation of biomarkers to support the assessment of novel therapeutics for COPD continues to be an important area of research. The aim of the current study was to identify systemic protein biomarkers correlated with measures of COPD severity, as well as specific protein sign...

Descripción completa

Detalles Bibliográficos
Autores principales: Cockayne, Debra A., Cheng, Donavan T., Waschki, Benjamin, Sridhar, Sriram, Ravindran, Palanikumar, Hilton, Holly, Kourteva, Galina, Bitter, Hans, Pillai, Sreekumar G., Visvanathan, Sudha, Müller, Kai-Christian, Holz, Olaf, Magnussen, Helgo, Watz, Henrik, Fine, Jay S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373533/
https://www.ncbi.nlm.nih.gov/pubmed/22701684
http://dx.doi.org/10.1371/journal.pone.0038629
_version_ 1782235484615868416
author Cockayne, Debra A.
Cheng, Donavan T.
Waschki, Benjamin
Sridhar, Sriram
Ravindran, Palanikumar
Hilton, Holly
Kourteva, Galina
Bitter, Hans
Pillai, Sreekumar G.
Visvanathan, Sudha
Müller, Kai-Christian
Holz, Olaf
Magnussen, Helgo
Watz, Henrik
Fine, Jay S.
author_facet Cockayne, Debra A.
Cheng, Donavan T.
Waschki, Benjamin
Sridhar, Sriram
Ravindran, Palanikumar
Hilton, Holly
Kourteva, Galina
Bitter, Hans
Pillai, Sreekumar G.
Visvanathan, Sudha
Müller, Kai-Christian
Holz, Olaf
Magnussen, Helgo
Watz, Henrik
Fine, Jay S.
author_sort Cockayne, Debra A.
collection PubMed
description The identification and validation of biomarkers to support the assessment of novel therapeutics for COPD continues to be an important area of research. The aim of the current study was to identify systemic protein biomarkers correlated with measures of COPD severity, as well as specific protein signatures associated with comorbidities such as metabolic syndrome. 142 protein analytes were measured in serum of 140 patients with stable COPD, 15 smokers without COPD and 30 non-smoking controls. Seven analytes (sRAGE, EN-RAGE, NGAL, Fibrinogen, MPO, TGF-α and HB-EGF) showed significant differences between severe/very severe COPD, mild/moderate COPD, smoking and non-smoking control groups. Within the COPD subjects, univariate and multivariate analyses identified analytes significantly associated with FEV(1), FEV(1)/FVC and DLCO. Most notably, a set of 5 analytes (HB-EGF, Fibrinogen, MCP-4, sRAGE and Sortilin) predicted 21% of the variability in DLCO values. To determine common functions/pathways, analytes were clustered in a correlation network by similarity of expression profile. While analytes related to neutrophil function (EN-RAGE, NGAL, MPO) grouped together to form a cluster associated with FEV(1) related parameters, analytes related to the EGFR pathway (HB-EGF, TGF-α) formed another cluster associated with both DLCO and FEV(1) related parameters. Associations of Fibrinogen with DLCO and MPO with FEV(1)/FVC were stronger in patients without metabolic syndrome (r  =  −0.52, p  = 0.005 and r  =  −0.61, p  = 0.023, respectively) compared to patients with coexisting metabolic syndrome (r  =  −0.25, p  = 0.47 and r  =  −0.15, p  = 0.96, respectively), and may be driving overall associations in the general cohort. In summary, our study has identified known and novel serum protein biomarkers and has demonstrated specific associations with COPD disease severity, FEV(1), FEV(1)/FVC and DLCO. These data highlight systemic inflammatory pathways, neutrophil activation and epithelial tissue injury/repair processes as key pathways associated with COPD.
format Online
Article
Text
id pubmed-3373533
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33735332012-06-14 Systemic Biomarkers of Neutrophilic Inflammation, Tissue Injury and Repair in COPD Patients with Differing Levels of Disease Severity Cockayne, Debra A. Cheng, Donavan T. Waschki, Benjamin Sridhar, Sriram Ravindran, Palanikumar Hilton, Holly Kourteva, Galina Bitter, Hans Pillai, Sreekumar G. Visvanathan, Sudha Müller, Kai-Christian Holz, Olaf Magnussen, Helgo Watz, Henrik Fine, Jay S. PLoS One Research Article The identification and validation of biomarkers to support the assessment of novel therapeutics for COPD continues to be an important area of research. The aim of the current study was to identify systemic protein biomarkers correlated with measures of COPD severity, as well as specific protein signatures associated with comorbidities such as metabolic syndrome. 142 protein analytes were measured in serum of 140 patients with stable COPD, 15 smokers without COPD and 30 non-smoking controls. Seven analytes (sRAGE, EN-RAGE, NGAL, Fibrinogen, MPO, TGF-α and HB-EGF) showed significant differences between severe/very severe COPD, mild/moderate COPD, smoking and non-smoking control groups. Within the COPD subjects, univariate and multivariate analyses identified analytes significantly associated with FEV(1), FEV(1)/FVC and DLCO. Most notably, a set of 5 analytes (HB-EGF, Fibrinogen, MCP-4, sRAGE and Sortilin) predicted 21% of the variability in DLCO values. To determine common functions/pathways, analytes were clustered in a correlation network by similarity of expression profile. While analytes related to neutrophil function (EN-RAGE, NGAL, MPO) grouped together to form a cluster associated with FEV(1) related parameters, analytes related to the EGFR pathway (HB-EGF, TGF-α) formed another cluster associated with both DLCO and FEV(1) related parameters. Associations of Fibrinogen with DLCO and MPO with FEV(1)/FVC were stronger in patients without metabolic syndrome (r  =  −0.52, p  = 0.005 and r  =  −0.61, p  = 0.023, respectively) compared to patients with coexisting metabolic syndrome (r  =  −0.25, p  = 0.47 and r  =  −0.15, p  = 0.96, respectively), and may be driving overall associations in the general cohort. In summary, our study has identified known and novel serum protein biomarkers and has demonstrated specific associations with COPD disease severity, FEV(1), FEV(1)/FVC and DLCO. These data highlight systemic inflammatory pathways, neutrophil activation and epithelial tissue injury/repair processes as key pathways associated with COPD. Public Library of Science 2012-06-12 /pmc/articles/PMC3373533/ /pubmed/22701684 http://dx.doi.org/10.1371/journal.pone.0038629 Text en Cockayne et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Cockayne, Debra A.
Cheng, Donavan T.
Waschki, Benjamin
Sridhar, Sriram
Ravindran, Palanikumar
Hilton, Holly
Kourteva, Galina
Bitter, Hans
Pillai, Sreekumar G.
Visvanathan, Sudha
Müller, Kai-Christian
Holz, Olaf
Magnussen, Helgo
Watz, Henrik
Fine, Jay S.
Systemic Biomarkers of Neutrophilic Inflammation, Tissue Injury and Repair in COPD Patients with Differing Levels of Disease Severity
title Systemic Biomarkers of Neutrophilic Inflammation, Tissue Injury and Repair in COPD Patients with Differing Levels of Disease Severity
title_full Systemic Biomarkers of Neutrophilic Inflammation, Tissue Injury and Repair in COPD Patients with Differing Levels of Disease Severity
title_fullStr Systemic Biomarkers of Neutrophilic Inflammation, Tissue Injury and Repair in COPD Patients with Differing Levels of Disease Severity
title_full_unstemmed Systemic Biomarkers of Neutrophilic Inflammation, Tissue Injury and Repair in COPD Patients with Differing Levels of Disease Severity
title_short Systemic Biomarkers of Neutrophilic Inflammation, Tissue Injury and Repair in COPD Patients with Differing Levels of Disease Severity
title_sort systemic biomarkers of neutrophilic inflammation, tissue injury and repair in copd patients with differing levels of disease severity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3373533/
https://www.ncbi.nlm.nih.gov/pubmed/22701684
http://dx.doi.org/10.1371/journal.pone.0038629
work_keys_str_mv AT cockaynedebraa systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity
AT chengdonavant systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity
AT waschkibenjamin systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity
AT sridharsriram systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity
AT ravindranpalanikumar systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity
AT hiltonholly systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity
AT kourtevagalina systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity
AT bitterhans systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity
AT pillaisreekumarg systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity
AT visvanathansudha systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity
AT mullerkaichristian systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity
AT holzolaf systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity
AT magnussenhelgo systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity
AT watzhenrik systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity
AT finejays systemicbiomarkersofneutrophilicinflammationtissueinjuryandrepairincopdpatientswithdifferinglevelsofdiseaseseverity